SLC5A2 and heart failure: In type 2 diabetic patients with a high CV risk or a history of severe CVD or advanced renal illness, SGLT2 inhibitors significantly prevent major adverse cardiovascular events, CV death, heart failure, and renal outcomes [64,65].